FDA on Novartis data manipulation controversy: ‘We happened to be lucky’
DOMINICK REUTER/AFP/GETTY IMAGES
A top agency official suggested that the FDA was so distressed by the matter in part because the stakes in gene therapy research are so high.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario